Cite
MLA Citation
Dirk Schadendorf et al.. “Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial.” Lancet oncology, vol. 20, no. 5, 2019, pp. 701–710. http://access.bl.uk/ark:/81055/vdc_100081476495.0x000011